MarginsXMarginsX
Home › Markets › Health Care › TKNO

Alpha Teknova Inc. (TKNO)

TKNO trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.77
-5.36% on the day
Market cap
$488.8M
Small cap
Revenue · 2025
$40.5M
+7.4% on 2024
Net income · 2025
-$17.3M
-42.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/0001850902-26-000002-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTKNO on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year2021
SEC CIK0001850902
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2025

LineValue
Revenue$40.5M
Net income-$17.3M
Operating income-$17.0M
Net margin-42.6%
Operating margin-41.9%
Revenue growth+7.4%
Cash$5.9M
Total assets$103.6M
P/E (computed)Net income was not positive
P/S (computed)12.1×

Warning signs

Cash runway
14.3 months
$6.6M cash at September 30, 2026
Share count, 1 year
+17.5%
2025-11-05 to 2026-11-04 · +54.4% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$144K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$6.6M cash; operating cash flow -$1.4M a quarter.Report 2026-09-30
Shares outstanding62,903,130 (2026-11-04); 53,529,174 a year earlier; 40,727,780 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-10-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $144K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$12.7M-$3.5M-$1.3M$6.6M$13.3M$46.0M10-Q 2026-11-05
Q2 2026
2026-06-30
$12.2M-$3.2M-$471K$6.0M$13.2M$43.7M10-Q 2026-08-06
Q1 2026
2026-03-31
$11.1M-$4.6M-$3.4M$4.3M$13.2M$41.8M10-Q 2026-05-07
Q4 2025
2025-12-31
$10.0M-$4.8M-$462K$5.9M$13.1M$40.5M10-K 2026-03-02
Q3 2025
2025-09-30
$10.5M-$4.3M-$2.0M$3.2M$13.1M$39.8M10-Q 2026-11-05
Q2 2025
2025-06-30
$10.3M-$3.6M-$2.1M$3.3M$13.0M$38.9M10-Q 2026-08-06
Q1 2025
2025-03-31
$9.8M-$4.6M-$4.1M$3.4M$13.0M$38.3M10-Q 2026-05-07
Q4 2024
2024-12-31
$9.3M-$5.7M-$936K$3.7M$9.4M$37.7M10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-21
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 222 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.1%
1 month-0.1%
3 months+11.2%
Year to date+116.1%
1 year+85.3%
From 52-week high-12.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
MYGNMyriad Genetics Inc.$5.57-1.59%$534.3M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
ICCCImmuCell Corporation$11.42+6.23%$103.8M
NEOGNeogen Corporation$10.88-3.12%$2.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier